Breaking Down the Success from the Padcev-Keytruda Combination & Applying Learnings to Future ADC-Immunotherapy Combinations
Time: 8:15 am
day: Day Two AM
Details:
- Highlighting safety and clinical outcome readouts from the Phase III combination trial in bladder cancer
- Breaking down strategy, rationale, partnering, and lessons learned advancing through preclinical and clinical strategies
- Evaluating the future of ADC-immunotherapy and other novel combinations with ADCs to redefine patient experience and standard of care
